Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.

European urology - 1 Jul 2017

Annala Matti, Struss Werner J, Warner Evan W, Beja Kevin, Vandekerkhove Gillian, Wong Amanda, Khalaf Daniel, Seppälä Irma-Liisa, So Alan, Lo Gregory, Aggarwal Rahul, Small Eric J, Nykter Matti, Gleave Martin E, Chi Kim N, Wyatt Alexander W

Abstract excerpt

BACKGROUND: Germline mutations in DNA repair genes were recently reported in 8-12% of patients with metastatic castration-resistant prostate cancer (mCRPC). It is unknown whether these mutations associate with differential response to androgen receptor (AR)-directed therapy. OBJECTIVE: To determine the clinical response of mCRPC patients with germline DNA repair defects to AR-directed therapies and to establish...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Kallikreins

Share to Liquid Biopsy

Share to Loss of Heterozygosity

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Source

Identifiers

PMID: 28259476
DOI: 10.1016/j.eururo.2017.02.023

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.PMID 28259476Read ↗

Treatment strategies for DNA repair-deficient prostate cancer.Semantic proximity Read ↗

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.Semantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

BRCAness and prostate cancer: diagnostic and therapeutic considerations.Semantic proximity Read ↗

DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentSemantic proximity Read ↗

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesSemantic proximity Read ↗

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.Semantic proximity Read ↗

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.Semantic proximity Read ↗

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.